Stryker Corp (SYK) Valuation

The primary valuation assessment reveals a significant disconnect between Stryker's market price and its estimated intrinsic value. The GoodMoat Target of $206.96 suggests the stock is trading at a 58% premium, which equates to a negative margin of safety. According to the GoodMoat framework, a margin of safety below 10% is considered unfavourable, and a negative value fails the valuation gate entirely. The forward P/E of 38.6x is elevated, especially when considered against an 11.4% revenue growth rate and a 12.9% profit margin. This P/E is likely high relative to both the sector average and the company's own historical range, indicating the market is pricing in near-perfect execution. While Stryker is a high-quality business in the medical device sector, its current valuation does not offer the margin of safety a value investor typically requires. The 3.4% free cash flow yield further supports the view that the stock is fully valued, as it provides a relatively low cash return on the investment price. For a value investor, the price paid is a critical component of the investment thesis, and at these levels, the risk/reward profile is not favourable. Analysis based on data as of 2024-05-15.